DiaCarta develops, manufactures and markets cancer research and IVD products for precision molecular diagnostics. Xeno nucleic acid (XNA) is the enabling technology that powers our QClamp® (qPCR) and OptiSeqTM (NGS) platforms for ultra-sensitive detection of genetic mutations in liquid biopsy samples. Our US facility is ISO13485 and CLIA-certified. We have also expanded our business and clinical operations in China. Learn more at www.diacarta.com.